A Study of Mavorixafor in Participants With Severe Congenital Neutropenia and Chronic Neutropenia Disorders
Status:
Recruiting
Trial end date:
2022-07-29
Target enrollment:
Participant gender:
Summary
This Phase 1b study will determine the safety and tolerability of mavorixafor in participants
with severe chronic idiopathic neutropenia (CIN) and selected congenital neutropenia
disorders. The anticipated enrollment is up to 25 participants.